



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Erythropoiesis Stimulating Proteins

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Questions Q1-Q7 regarding anemia diagnosis, therapy continuation, kidney disease, hemoglobin levels, pediatric status, specialist consultation, and hemoglobin increase.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Erythropoiesis Stimulating Proteins

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q8. Does the patient meet all of the following: 1) Hemoglobin less than or equal to 10 g/dL if the patient is not on dialysis, 2) Hemoglobin less than or equal to 11 g/dL for patients on dialysis, 3) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Does the patient have anemia while on chemotherapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Is this a request for continuation of therapy with the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Is the patient currently receiving myelosuppressive chemotherapy?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Does the patient meet all of the following: 1) Hemoglobin less than 10 g/dL, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Has the patient experienced a documented increase in hemoglobin?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Does the patient meet all of the following: 1) Hemoglobin less than or equal to 12 g/dL, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Will the requested drug be used to treat anemia in a patient taking zidovudine for human immunodeficiency virus (HIV) infection?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Is this a request for a continuation of therapy with the requested drug?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Is the patient receiving 4200 mg/week of zidovudine or greater?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Does the patient meet all of the following: 1) Serum erythropoietin level less than or equal to 500 mUnits/mL, 2) Hemoglobin less than or equal to 10 g/dL, 3) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Erythropoiesis Stimulating Proteins

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q19. Has the patient experienced a documented increase in hemoglobin?
Q20. Does the patient meet all of the following: 1) Hemoglobin less than or equal to 12 g/dL, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?
Q21. Will the requested drug be used to reduce allogenic blood transfusion in a surgical patient?
Q22. Is the patient undergoing elective, noncardiac, nonvascular surgery?
Q23. Does the patient meet all of the following: 1) Hemoglobin greater than 10 g/dL but less than or equal to 13 g/dL, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?
Q24. Will the requested drug be used to treat anemia caused by ribavirin in a patient being treated for hepatitis C?
Q25. Is this a request for a continuation of therapy with the requested drug?
Q26. Does the patient meet all of the following: 1) Hemoglobin less than 10 g/dL if asymptomatic, or hemoglobin less than 11 g/dL if symptomatic, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?
Q27. Has the patient experienced a documented increase in hemoglobin?
Q28. Does the patient meet all of the following: 1) Hemoglobin less than or equal to 12 g/dL, 2) Transferrin or iron saturation greater than or equal to 20 percent and ferritin greater than or equal to 100 ng/mL?
Q29. Has the provider evaluated the patient's vitamin B12 and folate levels and will supplement as indicated?
Q30. Does the patient have adequately controlled blood pressure?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Erythropoiesis Stimulating Proteins

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

Q31. Is the request for a non-preferred product?

Yes

No

Q32. Does the patient have a documented history of therapeutic failure, contraindication or intolerance of the preferred erythropoiesis stimulation proteins?

Yes

No

Q33. Additional Information:

Prescriber Signature

Date

Updated for 2020